PM360

DECEMBER 14, 2023

A standard dose of the medicine causes acute kidney damage in 20% of patients and 50% of those who receive higher dosages used to treat life-threatening infections on a broad spectrum. for adult patients with progressing desmoid tumors who require systemic treatment. The tablets are created by SpringWorks Therapeutics Inc.

Healthcare 52

Healthcare Healthcare FDA Education 52

PM360

DECEMBER 14, 2023

A New Online Destination for HCPs HealthCentral Corporation , operator of leading digital platforms that serve patients living with chronic illness, their care partners, and health professionals, has announced the newest addition to its suite of HCP support sites: MedCentral.

Physicians 52

Physicians Pharma Medical Patients 52

Legacy MEDSearch

MARCH 1, 2024

Food and Drug Administration (FDA) for treating coronary in-stent restenosis (ISR) in patients with coronary artery disease. physicians the opportunity to treat their patients with this novel device.” Yeh, MD, MSc, MBA, at TCT 2023, showed that target lesion failure after one year was observed in 28.7%

Food and Drug Administration 52

Food and Drug Administration FDA Recruitment Physicians 52

Pharmaceutical Technology

APRIL 17, 2023

The US Food and Drug Administration (FDA) has approved an update to the indications and usage section of Horizon Therapeutics ’ Tepezza (teprotumumab-trbw) label to specify its use to treat thyroid eye disease (TED) patients regardless of disease activity or duration. The FDA’s approval was granted in January 2020.

Food and Drug Administration 52

Food and Drug Administration FDA Physicians Food 52

Pharma Leaders

MAY 18, 2023

The US Food and Drug Administration (FDA) has accepted Ardelyx’s resubmitted New Drug Application (NDA) for XPHOZAH (tenapanor) to control serum phosphate in adult patients with chronic kidney disease on dialysis who have had an insufficient response or intolerance to a phosphate binder therapy.

Food and Drug Administration 52

Food and Drug Administration FDA Side effects Prospecting 52

PM360

SEPTEMBER 7, 2023

HCPs are depending on developers’ promised changes to make the platform more patient focused. Also, the platform holds promise as a more effective way for healthcare professionals to engage directly with patients. Despite these concerns, some HCPs are feeling positively about Threads. Ask me anything!” Tarsus Pharmaceuticals, Inc.

Healthcare 52

Healthcare Healthcare FDA Doctors 52

Pharmaceutical Technology

JUNE 14, 2023

Ipsen has received US Food and Drug Administration (FDA) approval for Bylvay (odevixibat) to treat patients aged 12 months and above with cholestatic pruritus caused by Alagille syndrome (ALGS). More than 90% of patients who received treatment with odevixibat were pruritus responders.

Food and Drug Administration 52

Food and Drug Administration FDA Transportation Prescription 52

pharmaphorum

SEPTEMBER 30, 2022

Patient organisations have been celebrating the FDA approval yesterday of Amylyx’ amyotrophic lateral sclerosis (ALS) therapy Relyvrio, after not one but two advisory committee meetings that arrived at different conclusions about the drug. An oral version of edaravone was cleared this year.

FDA 87

FDA Doctors Patients Prescription 87

PM360

APRIL 22, 2024

Furthermore, a 2023 FDA-backed study found that many HCPs do not accurately interpret clinical trial data presented with certain visual graphics, such as graphs and figures with complex features, and that this uncertainty may impact their prescribing decisions. References: Physician Learning Preferences: A Doximity Report.

Physicians 52

Physicians Education Healthcare Healthcare 52

pharmaphorum

SEPTEMBER 29, 2022

A digital patient monitoring tool developed by UK company CyberLiver has been given a breakthrough designation by the FDA for out-of-hospital management of patients with cirrhosis at risk of complications. The post Digital tool cuts hospital readmissions in cirrhosis patients appeared first on.

Patients 52

Patients Management Consulting FDA 52

pharmaphorum

JULY 18, 2022

The Dutch biotech submitted the ADC to the FDA last week and said this morning the EMA had formally started its review of the drug for HER2-positive, locally advanced or metastatic breast cancer that can’t be treated with surgery. “There is a dire need to provide an alternative treatment option to these patients.”

Side effects 57

Side effects Physicians FDA Marketing 57

Legacy MEDSearch

JANUARY 13, 2023

Hip Innovation Technology , LLC (HIT), a medical device company developing innovative orthopaedic device solutions to advance the quality of life and quality of care for patients, is pleased to announce the first U.S. Safety will be assessed through the collection of device-related adverse events and patient quality of life metrics.

FDA 98

FDA Safety Recruitment Patients 98

PM360

MAY 15, 2023

Doctor Docs: Incorporating Climate Change into Physician Training A growing number of medical professionals across the U.S. FDA Update Drug Approvals The FDA approved Qalsody (tofersen) to treat patients with ALS that is associated with a mutation in the superoxide dismutase 1 (SOD1) gene.

Healthcare 52

Healthcare Healthcare Medical Education 52

Legacy MEDSearch

MARCH 17, 2023

a health technology company equipping primary care physicians (PCPs) with a non-invasive device for use in evaluation of suspicious skin lesions, presented a pooled analysis today from two clinical studies evaluating the performance of the company’s device in detecting skin cancer. Dr. Grant-Kels is the 2023 recipient of the Clarence S.

FDA 52

FDA Physicians Recruitment Medical 52

European Pharmaceutical Review

MARCH 4, 2024

Indeed, in 2022, biologics constituted 40 percent of all US Food and Drug Administration (FDA) approved drugs, projecting a compound annual growth rate (CAGR) of 9.5 The emergency use approval from the FDA of lipid nanoparticle- (LNP-) based mRNA vaccines during the COVID-19 pandemic attested the significance of LNPs.

Food and Drug Administration 88

Food and Drug Administration Transportation FDA Medical 88

Legacy MEDSearch

APRIL 27, 2023

(Innoblative), a private medical device company addressing clinical unmet needs for patients with breast cancer, announced that it received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the company’s SIRA RFA Electrosurgical Device (SIRA). For more information, visit Innoblative.com.

FDA 52

FDA Food and Drug Administration Recruitment Medical 52

Legacy MEDSearch

FEBRUARY 24, 2023

SENSORA currently features AI that objectively identifies structural murmurs, a sign of valvular heart disease, and Care Pathway Analytics software that provides downstream visibility and metrics of the patient journey through the healthcare system. We are making the world’s most universal medical exam objective and accurate.”

Physicians 98

Physicians Recruitment Patients FDA 98

Legacy MEDSearch

AUGUST 21, 2023

It is the next generation of highly crosslinked polyethylene with vitamin E antioxidant that is intended to further our primary goal of providing immense benefits to our patients.” The first products for Activit-E will launch in the beginning of Q3 2023 for select U.S. Global expansion will begin in 2024. Are you hiring?

Food and Drug Administration 52

Food and Drug Administration FDA Recruitment Marketing 52

European Pharmaceutical Review

DECEMBER 6, 2023

The US Food and Drug Administration (FDA) has approved the first oral monotherapy treatment for adults with paroxysmal nocturnal haemoglobinuria (PNH). The first, the Phase III APPLY-PNH trial evaluated patients with residual anaemia (haemoglobin < 10 g/dL) despite prior anti-C5 treatment who switched to Fabhalta.

Food and Drug Administration 84

Food and Drug Administration Patients Physicians Food 84

PM360

SEPTEMBER 21, 2023

The recent wave of Alzheimer’s Disease (AD) drug approvals and promising pivotal trial data from various drug manufacturers has been celebrated by physicians, patients, caregivers, and advocacy groups across the U.S. 2 Yet the largest payer in the U.S. has seemingly taken a different point of view.

Manufacturing 99

Manufacturing FDA Recruitment Prospecting 99

Legacy MEDSearch

OCTOBER 13, 2022

Food and Drug Administration (FDA) for the Senza HFX iQ spinal cord stimulation (SCS) system. Senza HFX iQ is the first and only Artificial Intelligence-based SCS system that learns from patients. “Pain is variable from patient to patient and over time. market launch planned for early 2023.

FDA 52

FDA Food and Drug Administration Recruitment Pharmacology 52

Clarivate

JULY 5, 2023

The month of July could see seven FDA-approved adalimumab biosimilars launch in the United States, an unprecedented situation for a market that has been relatively slow to embrace biosimilars. When AMJETIVA finally launched at the end of January 2023, its unusual, tiered pricing strategy made headlines. from 91% in 2023 to 36% by 2031.

Marketing 97

Marketing Physicians Manufacturing Competition 97

Legacy MEDSearch

FEBRUARY 28, 2023

RADIANCE II is a randomized, sham-controlled US FDA IDE pivotal trial of the Paradise uRDN System in the treatment of patients with uncontrolled hypertension. Patients were to remain off antihypertensive medications throughout the two months of follow-up unless specified BP criteria were exceeded. mmHg (p<0.0001).

Networking 98

Networking Medical Physicians Safety 98

Pharmaceutical Technology

MARCH 24, 2023

Amgen’s (US) Amjevita (adalimumab) is the first Humira biosimilar, launched in February 2023, and seven other FDA-approved biosimilars are expected to arrive on the US market later this year. In addition, two more Humira biosimilars are currently under FDA review and both are anticipated to launch in 2023.

Competition 59

Competition Marketing FDA Physicians 59

PM360

NOVEMBER 12, 2023

Macroeconomic Factors The pandemic really changed the game, driven by several disruptions that changed physician and patient behavior forever. Long patient journeys, seen in many rare diseases and oncologic tumors, were disrupted enough that it will take years to catch up. of claims for care were via telemedicine.

Physicians 64

Physicians Marketing Sales Pharma 64

Pharmaceutical Technology

MARCH 29, 2023

The company hopes for results to be available in the second half of 2023. In that trial, the drug demonstrated positive signs of clinical activity – all patients receiving VK2735 reported a loss in mean body weight. The FDA had granted the drug a Fast Track designation to the drug to tackle obesity.

Marketing 105

Marketing Physicians FDA Management 105

Legacy MEDSearch

NOVEMBER 6, 2023

This payment rate supports hospitals and physicians using the non-invasive histotripsy procedure in the outpatient setting to destroy targeted liver tumors while existing Diagnosis Related Group (DRG) payment rates are applicable for patients who require hospital admission.

Recruitment 52

Recruitment Physicians Medical Patients 52

European Pharmaceutical Review

JULY 13, 2023

In many European countries physicians can now prescribe medical cannabis for an array of chronic health conditions, including chronic pain, mental health disorders and neurological conditions. It is estimated that only one in 10 drugs that enter Phase I trials are subsequently licensed by the US Food and Drug Administration (FDA).

Medical 85

Medical Food and Drug Administration Pharmacology Medicine 85

Legacy MEDSearch

SEPTEMBER 20, 2023

a medical imaging company focused on improving the treatment and outcomes for patients with coronary artery disease (CAD), today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for product enhancements to the HyperVue Imaging System. Intravascular imaging is essential to optimize patient outcomes,“ said Richard A.

Food and Drug Administration 52

Food and Drug Administration Recruitment Physicians Patients 52

European Pharmaceutical Review

DECEMBER 1, 2023

This is also evident from the number of US Food and Drug Administration (FDA) approvals and European Medicines Agency (EMA) approvals, which still show a large number of approvals on the small molecule side. So, because of the large molecule size, the difficulty was with absorption through the oral delivery system.

Food and Drug Administration 83

Food and Drug Administration Manufacturing Pharma Patients 83

European Pharmaceutical Review

NOVEMBER 8, 2022

For example, the US recently passed the Inflation Reduction Act, 1 which requires the Secretary of Health and Human Services (HHS) to negotiate prices for certain physician-administered and retail prescription drugs covered under Medicare Parts B and D. Citizen Petitions before the FDA. 5) monitoring access to biosimilars.

Food and Drug Administration 52

Food and Drug Administration Pharma Prescription Manufacturing 52

Pharmaceutical Technology

MAY 9, 2023

On April 26, Eli Lilly, Novo Nordisk’s clearest rival in this multi-billion-dollar market, revealed overwhelmingly positive data for its own GLP-1 drug Mounjaro (tirzepatide) from the Phase III SURMOUNT-2 trial examining the drug’s effectiveness in helping obese or overweight diabetic patients lose weight. The average patient lost 15.7%

Marketing 59

Marketing Manufacturing Prospecting Physicians 59

PM360

AUGUST 9, 2022

How can we help ensure patients continue to take their medications as prescribed? The reasons why a patient may not take their medication are plentiful, and as a result so are the solutions now available to attempt to solve this issue. But it is not a simple answer. Furthermore, it is estimated to reach $6.5

Prescription 105

Prescription Medical Side effects Patients 105

pharmaphorum

SEPTEMBER 16, 2022

Atopic dermatitis (AD) is a highly prevalent chronic dermatological disease, with symptoms which include itching, dry skin, severe pain, and inflammation – all of which create considerable stress in the daily lives of patients and often negatively affect their day-to-day and long-term well-being. However, side effects do happen.

Management 78

Management Side effects Patients Safety 78

PM360

SEPTEMBER 7, 2023

The “Kama Sutra” for Parkinson’s patients. A card game designed to help hemophilia patients exercise. A virtual product launch for patients akin to an iPhone debut. All of these are examples of how companies are taking a little more unconventional approach to patient engagement. Marketing and Patient Engagement, argenx.

Patients 105

Patients Pharma Education Doctors 105

Nixon Gwilt Law

JULY 15, 2022

In the Spring of 2022, the Centers for Medicare and Medicaid Services (“CMS”) released its 2022 Behavioral Health Strategy (the “BH Strategy”) to increase access to care and improve patient outcomes. We now see this evolution continuing in the 2023 Proposed Rule.

Physicians 52

Physicians Management Patients Electronics 52

European Pharmaceutical Review

SEPTEMBER 28, 2023

The US Food and Drug Administration (FDA) has approved Takeda’s single-dose pre-filled pen for ENTYVIO ® (vedolizumab) as a treatment for the chronic inflammatory disease ulcerative colitis. FDA’s approval is based on the Phase III VISIBLE 1 study (SC UC Trial).

Food and Drug Administration 83

Food and Drug Administration FDA Physicians Food 83